Feb 28 |
Knight Therapeutics Inc. Celebrates its First Decade of Success
|
Feb 21 |
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil
|
Feb 6 |
Knight Therapeutics Announces Launch of Bijuva® in Canada
|
Feb 4 |
Knight Therapeutics Inc.'s (TSE:GUD) top owners are retail investors with 43% stake, while 23% is held by private companies
|
Jan 25 |
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
|
Jan 4 |
Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada
|
Dec 19 |
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada
|
Nov 9 |
Knight Therapeutics Reports Third Quarter 2023 Results
|
Nov 2 |
Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call
|
Oct 30 |
Knight Therapeutics (TSE:GUD) investors are sitting on a loss of 44% if they invested five years ago
|